Overexpression of CD73 in pancreatic ductal adenocarcinoma is associated with immunosuppressive tumor microenvironment and poor survival.

[1]  S. Jalkanen,et al.  Prognostic impact of CD73 expression and its relationship to PD-L1 in patients with radically treated pancreatic cancer , 2020, Virchows Archiv.

[2]  J. Bowser,et al.  CD73's Potential as an Immunotherapy Target in Gastrointestinal Cancers , 2020, Frontiers in Immunology.

[3]  D. Pe’er,et al.  Immune profiling of human tumors identifies CD73 as a combinatorial target in glioblastoma , 2019, Nature Medicine.

[4]  P. Ascierto,et al.  CD73 expression and pathologic response to neoadjuvant chemotherapy in triple negative breast cancer , 2019, Virchows Archiv.

[5]  J. Bergh,et al.  CD73 Immune Checkpoint Defines Regulatory NK-cells within the Tumor Microenvironment. , 2019, The Journal of clinical investigation.

[6]  M. Oyama,et al.  CD73 complexes with emmprin to regulate MMP-2 production from co-cultured sarcoma cells and fibroblasts , 2019, BMC Cancer.

[7]  D. Allard,et al.  Targeting the adenosine pathway for cancer immunotherapy. , 2019, Seminars in immunology.

[8]  Liangjing Zhou,et al.  The distinct role of CD73 in the progression of pancreatic cancer , 2019, Journal of Molecular Medicine.

[9]  C. Iacobuzio-Donahue,et al.  Comparison of immune infiltrates in melanoma and pancreatic cancer highlights VISTA as a potential target in pancreatic cancer , 2019, Proceedings of the National Academy of Sciences.

[10]  C. Sempoux,et al.  CD73 expression in normal and pathological human hepatobiliopancreatic tissues , 2019, Cancer Immunology, Immunotherapy.

[11]  P. Boström,et al.  Cell-type-specific CD73 expression is an independent prognostic factor in bladder cancer , 2018, Carcinogenesis.

[12]  R. Salgia,et al.  Development of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: a comprehensive review of registration trials and future considerations , 2018, Journal of Immunotherapy for Cancer.

[13]  C. Sotiriou,et al.  Clinical significance of CD73 in triple-negative breast cancer: multiplex analysis of a phase III clinical trial , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

[14]  Jeffrey E. Lee,et al.  Prognostic Significance of Tumor-Infiltrating Lymphocytes in Patients With Pancreatic Ductal Adenocarcinoma Treated With Neoadjuvant Chemotherapy , 2017, Pancreas.

[15]  Ludmila V. Danilova,et al.  Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade , 2017, Science.

[16]  Adam A. Margolin,et al.  Quantitative Multiplex Immunohistochemistry Reveals Myeloid-Inflamed Tumor-Immune Complexity Associated with Poor Prognosis. , 2017, Cell reports.

[17]  K. Olive,et al.  Current and Emerging Therapies in Metastatic Pancreatic Cancer , 2017, Clinical Cancer Research.

[18]  H. Sugimura,et al.  Prognostic impact of CD73 and A2A adenosine receptor expression in non-small-cell lung cancer , 2017, Oncotarget.

[19]  T. Ji,et al.  CD73 as a novel marker for poor prognosis of oral squamous cell carcinoma , 2016, Oncology letters.

[20]  R. Broaddus,et al.  Loss of CD73-mediated actin polymerization promotes endometrial tumor progression. , 2015, The Journal of clinical investigation.

[21]  Deena M. A. Gendoo,et al.  CD73 is associated with poor prognosis in high-grade serous ovarian cancer. , 2015, Cancer research.

[22]  T. Hermanns,et al.  CD73 Predicts Favorable Prognosis in Patients with Nonmuscle-Invasive Urothelial Bladder Cancer , 2015, Disease markers.

[23]  F. Saad,et al.  CD73 Expression Is an Independent Prognostic Factor in Prostate Cancer , 2015, Clinical Cancer Research.

[24]  Dirk Schadendorf,et al.  Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. , 2015, The New England journal of medicine.

[25]  Bert Vogelstein,et al.  PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. , 2015, The New England journal of medicine.

[26]  G. Linette,et al.  Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. , 2015, The New England journal of medicine.

[27]  P. Sharma,et al.  Immune Checkpoint Targeting in Cancer Therapy: Toward Combination Strategies with Curative Potential , 2015, Cell.

[28]  Bin Zhang,et al.  The expression and clinical significance of CD73 molecule in human rectal adenocarcinoma , 2015, Tumor Biology.

[29]  S. Loi,et al.  CD73 promotes anthracycline resistance and poor prognosis in triple negative breast cancer , 2013, Proceedings of the National Academy of Sciences.

[30]  R. Vonderheide,et al.  Inflammatory networks and immune surveillance of pancreatic carcinoma. , 2013, Current opinion in immunology.

[31]  Yitian Chen,et al.  Expression and clinical significance of CD73 and hypoxia-inducible factor-1α in gastric carcinoma. , 2013, World journal of gastroenterology.

[32]  Jung-Hye Choi,et al.  Overexpression of CD73 in epithelial ovarian carcinoma is associated with better prognosis, lower stage, better differentiation and lower regulatory T cell infiltration , 2012, Journal of gynecologic oncology.

[33]  Xiaojian Wu,et al.  High expression of CD73 as a poor prognostic biomarker in human colorectal cancer , 2012, Journal of surgical oncology.

[34]  C. Drake,et al.  Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. , 2012, The New England journal of medicine.

[35]  H. Arakawa,et al.  Current Immunotherapeutic Approaches in Pancreatic Cancer , 2011, Clinical & developmental immunology.

[36]  S. Jalkanen,et al.  Altered purinergic signaling in CD73‐deficient mice inhibits tumor progression , 2011, European journal of immunology.

[37]  M. Smyth,et al.  CD73-deficient mice have increased antitumor immunity and are resistant to experimental metastasis. , 2011, Cancer research.

[38]  S. Rosenberg,et al.  Phase 2 Trial of Single Agent Ipilimumab (Anti-CTLA-4) for Locally Advanced or Metastatic Pancreatic Adenocarcinoma , 2010, Journal of immunotherapy.

[39]  C. Compton,et al.  The American Joint Committee on Cancer: the 7th Edition of the AJCC Cancer Staging Manual and the Future of TNM , 2010, Annals of Surgical Oncology.

[40]  Carmen Drahl.  NOBEL PRIZE IN PHYSIOLOGY OR MEDICINE: AWARDS: Three win for work on telomere biochemistry , 2009 .

[41]  S. Colgan,et al.  Physiological roles for ecto-5’-nucleotidase (CD73) , 2006, Purinergic Signalling.

[42]  S. Colgan,et al.  Ecto-5'-nucleotidase (CD73) regulation by hypoxia-inducible factor-1 mediates permeability changes in intestinal epithelia. , 2002, The Journal of clinical investigation.

[43]  A. Ohta,et al.  Role of G-protein-coupled adenosine receptors in downregulation of inflammation and protection from tissue damage , 2001, Nature.

[44]  V. Natarajan,et al.  [The Nobel Prize in physiology or medicine]. , 1998, Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke.

[45]  A. Jemal,et al.  Cancer statistics, 2018 , 2018, CA: a cancer journal for clinicians.